| HOME >> BIOLOGY >> TECHNOLOGY |
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE), creators of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that John J. Carbone, MD has been appointed to the Board of Directors. Dr. Carbone fills the vacancy left by the resignation of Murray Gross on February 13, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)
Michael L. Krall, President/CEO and Chairman of PURE Bioscience, commented, "We believe that SDC has tremendous potential in numerous healthcare applications, and we are extremely pleased and honored to have someone with Dr. Carbone's experience and leadership on our Board. Dr. Carbone's guidance will be a great benefit to PURE in our efforts to fully develop a market for SDC in healthcare."
Dr. Carbone stated, "I have always been fascinated with new technologies in my field, and I think that the SDC molecule presents intriguing and promising opportunities in medicine. I'm looking forward to supporting the research for and commercialization of SDC in medicine."
Dr. Carbone is a Board Certified Orthopedic Surgeon and a Fellow of the American Academy of Orthopedic Surgeons. Since 2004 he has served as the Director, Orthopedic Spine Services at Harbor Hospital in Baltimore, MD.
Dr. Carbone specializes in the design and use of orthopedic implants and surgical instruments as well as the biomechanics and clinical outcomes of spinal surgery. Currently, he holds several patents for orthopedic prosthetic devices and implants and is a consulting surgeon to the National Aquarium in Baltimore, MD. Dr. Carbone specializes in the treatment of all types of spinal pathology from degenerative cervical and lumbar disease to re
'/>"/>
| SOURCE PURE Bioscience Copyright©2009 PR Newswire. All rights reserved |